Innocept Biomaterials, Inc.
Min Sheu has received his Ph.D. in Bioengineering from University of Washington at Seattle, WA, USA. Since graduation, he has led several teams in R&D of various companies in the medical device industry, including AST Products, Boston Scientific Corp., Atrium Medical (acquired by Maquet Getinge Group) and Covidien (merged with Metronic). He has skillful experience in the development of medical devices, including drug eluting ureteral stents, drug coated stents, antimicrobial and antithrombogenic dialysis catheters, biocompatible flow diverters and vascular embolization implants. His primary expertise is in the development of Class III biomaterial implants, drug-device combination products and medical coatings, and he has over 12 issued and 16 pending US patents as well as 16 peer-reviewed publications in these areas. Recently, Dr. Sheu founded a new company in Taiwan, InnoCept Biomaterials, Inc., to develop novel biomaterial implants for vascular and cancer therapies. InnoCept was later acquired by Sunmax Biotechnology, Co., Ltd., a collagen-based medical device company in Taiwan. Currently, Dr. Sheu serves as the General Manager of Sunmax Biotechnology.
Biomaterials, medical devices, combination product and drug delivery; Surface coating technologies for medical device, drug delivery and tissue engineering; Wound healing and soft tissue repair; Vascular and tumor embolization